Inhibitor Therapeutics, Inc.
INTI
$0.049
-$0.0006-1.21%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.58% | -26.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.14% | -54.55% | |||
| Operating Income | -3.14% | 54.55% | |||
| Income Before Tax | -4.28% | 55.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.28% | 55.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.28% | 55.49% | |||
| EBIT | -3.14% | 54.55% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -2.70% | 55.42% | |||
| Normalized Basic EPS | -4.35% | 55.77% | |||
| EPS Diluted | -2.70% | 55.42% | |||
| Normalized Diluted EPS | -4.35% | 55.77% | |||
| Average Basic Shares Outstanding | 0.15% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.15% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||